McClung David
Known title: Chief Financial OfficerCIK: 0001686155
McClung David's purchase track record
How the stock did after each of McClung David's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since October 10, 2022
Stock higher 6 months later
0%
3 months: 67%
Median 6-month return
-21.5%
3 months: +10.1%
Beat the S&P 500
0%
median -46.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2025 | BCDA | $10K | -28.2% | -36.9% | +11.3% |
| 4/23/2025 | BCDA | $25K | +29.0% | -21.5% | +24.6% |
| 10/10/2022 | BCDA | $4K | +10.1% | -3.9% | +13.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BCDA | ▼ Sell | Tax Withholding | 23,125 | $29K | 7/2/2026 | View on chart |
| BCDA | ▲ Buy | Grant | 60,483 | $73K | 6/29/2026 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 29,339 | $40K | 12/8/2025 | View on chart |
| BCDA | ▲ Buy | Grant | 58,276 | $80K | 12/8/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 4,819 | $10K | 6/30/2025 | View on chart |
| BCDA | ▲ Buy | Open Market | 13,123 | $25K | 4/23/2025 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 11,565 | $31K | 10/11/2024 | View on chart |
| BCDA | ▲ Buy | Grant | 24,193 | $64K | 10/11/2024 | View on chart |
| BCDA | ▲ Buy | Grant | 8,333 | $25K | 9/3/2024 | View on chart |
| BCDA | ▲ Buy | Grant | 4,280 | $10K | 6/23/2023 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 20,676 | $37K | 5/31/2023 | View on chart |
| BCDA | ▲ Buy | Grant | 61,389 | $104K | 5/18/2023 | View on chart |
| BCDA | ▲ Buy | Grant | 8,928 | $15K | 12/16/2022 | View on chart |
| BCDA | ▲ Buy | Open Market | 2,000 | $4K | 10/10/2022 | View on chart |
| BCDA | ▼ Sell | Tax Withholding | 20,632 | $27K | 5/12/2022 | View on chart |
| BCDA | ▲ Buy | Grant | 50,345 | $0 | 4/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioCardia Resubmits Helix Catheter Pre-Submission to FDA
BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.
BioCardia Resubmits Helix Catheter Pre-Submission to FDA. BioCardia has filed a revised de‑novo pre‑submission and resubmitted a pre‑submission to the FDA for its Helix catheter, a device intended for therapeutic and diagnostic agent delivery to the heart. The filings are part of the regulatory pathway needed before the product can reach the market. The move is a significant step in the company’s development program and could influence investor perception of the company’s progress.